WillItSurvive
Medical technology and health companies · subsidiary of Blackstone / TPG (jointly owned via acquisition funds) · United States

Hologic

hologic.com ↗

Maker of 3D mammography systems and diagnostic tests for women's health.

Defensible for now
Assessed 22 July 2026 · Evidence as of 22 July 2026
Real protection, with named pressure against it.
On the recordSince 22 July 2026 · Checkable from April 2027 · Every call on the record Checkpoint: First 12 months of Blackstone/TPG ownership under CEO Almeida reveal which units get cut, sold, or invested in
The call

Hologic still leads breast imaging on patents and installed base, while new private owners and rival AI tools test how long that lead holds.

Hologic sells mammography machines and diagnostic software, mostly to hospitals and imaging centers for detecting breast cancer. Its position is hard to displace because it has 7,000 installed machines, government approvals, and patent protection against competitors like Siemens and GE Healthcare, though those rivals are working on AI software (like GE's MyBreastAI) that could eventually make Hologic's technology feel less special. The big unknown is whether the Blackstone and TPG buyout announced for April 2026 will distract management and force cost-cutting that hurts the business, or whether the deal will proceed smoothly and let Hologic invest in new features to stay ahead.

Why
01
AI pressure: GE HealthCare MyBreastAI Suite (with iCAD ProFound AI). GE's AI overlay competes directly with Hologic's Genius AI, threatening to turn breast-imaging software into a commodity add-on. Could AI do the core job? Unlikely.
02
Bigger players: Siemens Healthineers and GE HealthCare. Both sell competing mammography and breast-imaging systems; Hologic won a patent injunction against Siemens in June 2026. Could a giant copy it? Probably.
03
What protects it. FDA and CE approvals plus 7,000+ installed 3D mammography systems keep hospitals locked into Hologic's workflow and data.
What would change this call
Hologic divests Skeletal Health or GYN Surgical segment within 12 months of April 2026 close. Would show PE owners are running a leverage-and-strip play, not hold-and-grow.
Siemens Healthineers appeals or wins reversal of the June 2026 UPC injunction. Would show Hologic's patent moat is less enforceable than claimed.
Breast Health segment revenue misses FY26-27 CVR targets tied to the buyout. Would signal sponsor confidence in core franchise is weakening.
Key numbers
  • $18.3B Blackstone/TPG buyout closed April 7, 2026 (2026-04-07)
  • Q4 FY2025 revenue $1,049.5M, up 6.2% YoY (2025-11-03)
  • 7,070 employees at FY2025 year end (2025-09-27)
Named risks
  • PE-driven restructuring or asset divestiture under Blackstone/TPG ownership in first 12 months. Severity: high
  • Class 2 recall of ~14,837 mammography units could escalate if adverse events reported. Severity: medium
  • Siemens Healthineers appeal or counter-litigation against June 2026 UPC injunction. Severity: medium
  • Third-party AI overlays (GE MyBreastAI, iCAD) commoditizing Genius AI differentiation. Severity: medium
  • Reduced public financial disclosure post-privatization limits external monitoring. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
Siemens Healthineersgaining onWon UPC injunction June 2026 forcing Siemens to halt MAMMOMAT B.brilliant sales in 3 countries
GE HealthCarecontestingGE's MyBreastAI Suite (Nov 2023, with iCAD ProFound AI) competes directly with Hologic's Genius AI
Danaher (Mammotome)contestingDirect breast-biopsy device competitor per 2026 market reports
Questions people ask
Is Hologic still a public company in 2026?
No. Hologic delisted from Nasdaq (HOLX) on April 7, 2026 after Blackstone and TPG completed an $18.3B acquisition, taking the women's health diagnostics maker private with new CEO Jose Almeida replacing longtime CEO Stephen MacMillan.
Who owns Hologic now?
Blackstone and TPG completed their acquisition of Hologic on April 7, 2026 for $76 cash plus up to $3 in contingent value rights per share (~$18.3B including debt). Abu Dhabi Investment Authority and GIC affiliates hold minority stakes.
Is Hologic profitable?
Yes as of its last public quarter. Q4 FY2025 (ended Sept 27, 2025) revenue was $1,049.5M, up 6.2% YoY, with GAAP diluted EPS of $0.83 and non-GAAP EPS of $1.13. Full FY2025 revenue reached $4.10B, up 1.7%.
Could AI replace Hologic's mammography business?
Unlikely to fully replace it. Hologic's FDA-cleared hardware, ~7,000+ installed 3D mammography systems, and patent portfolio (used to win a June 2026 injunction against Siemens) create durable moats, though rival AI overlays like GE's MyBreastAI (launched Nov 2023) threaten to commoditize the AI-detection layer.
Who is Hologic's biggest competitor?
Siemens Healthineers and GE HealthCare are Hologic's chief rivals in mammography and breast imaging. Hologic won a Unified Patent Court injunction against Siemens in June 2026, forcing a halt to Siemens' MAMMOMAT B.brilliant sales in Germany, France, and the Netherlands.
Has Hologic had layoffs recently?
No confirmed mass layoffs are documented. Hologic's own FY2025 10-K shows 7,070 employees as of Sept 27, 2025, roughly flat versus 7,063 in FY2024, though third-party estimates (Revelio Labs) put a December 2025 count near 7,411, down 2.5% from 2023.
Timeline
  • 2026-07-13Aptima HPV Test CE-IVDR mark expanded to self-collected samples in EU/UK
  • 2026-06-16Won Unified Patent Court injunction forcing Siemens to halt/recall MAMMOMAT B.brilliant in 3 countries
  • 2026-05-11Class 2 FDA recall of ~14,837 3Dimensions/Selenia Dimensions mammography units
  • 2026-04-07Blackstone/TPG completed $18.3B acquisition; Jose Almeida named CEO, replacing Stephen MacMillan
  • 2026-02-05Stockholders approved the Blackstone/TPG merger at special meeting
  • 2025-12-27Q1 FY2026 revenue $1,047.8M, +2.5% YoY, last quarter reported as public company
  • 2025-11-03Q4 FY2025 results: revenue $1,049.5M, GAAP EPS $0.83; company stopped issuing forward guidance
  • 2025-10-21Blackstone/TPG go-private deal announced
  • 2025-09-27FY2025 closed with $4.10B revenue and 7,070 employees
  • 2024-09-30FDA approved 3DQuorum tomosynthesis technology, cutting image volume 66%
Revision history
22 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
AbridgeSeegeneOlympus Corporation
More in Medical technology and health companies →
Sources